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Abstract
Background: While 16S ribosomal RNA (rRNA) sequencing has been used to characterize the lung’s bacterial
microbiota in human immunodeficiency virus (HIV)-infected individuals, taxonomic studies provide limited
information on bacterial function and impact on the host. Metabolic profiles can provide functional information on
host-microbe interactions in the lungs. We investigated the relationship between the respiratory microbiota and
metabolic profiles in the bronchoalveolar lavage fluid of HIV-infected and HIV-uninfected outpatients.
Results: Targeted sequencing of the 16S rRNA gene was used to analyze the bacterial community structure and liquid
chromatography-high-resolution mass spectrometry was used to detect features in bronchoalveolar lavage fluid. Global
integration of all metabolic features with microbial species was done using sparse partial least squares regression.
Thirty-nine HIV-infected subjects and 20 HIV-uninfected controls without acute respiratory symptoms were enrolled.
Twelve mass-to-charge ratio (m/z) features from C18 analysis were significantly different between HIV-infected
individuals and controls (false discovery rate (FDR) = 0.2); another 79 features were identified by network analysis.
Further metabolite analysis demonstrated that four features were significantly overrepresented in the bronchoalveolar
lavage (BAL) fluid of HIV-infected individuals compared to HIV-uninfected, including cystine, two complex
carbohydrates, and 3,5-dibromo-L-tyrosine. There were 231m/z features significantly associated with peripheral blood
CD4 cell counts identified using sparse partial least squares regression (sPLS) at a variable importance on projection
(VIP) threshold of 2. Twenty-five percent of these 91m/z features were associated with various microbial species.
Bacteria from families Caulobacteraceae, Staphylococcaceae, Nocardioidaceae, and genus Streptococcus were associated
with the greatest number of features. Glycerophospholipid and lineolate pathways correlated with these bacteria.
Conclusions: In bronchoalveolar lavage fluid, specific metabolic profiles correlated with bacterial organisms known to
play a role in the pathogenesis of pneumonia in HIV-infected individuals. These findings suggest that microbial
communities and their interactions with the host may have functional metabolic impact in the lung.
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Background
Combination anti-retroviral therapy (ART) has reduced
the incidence of opportunistic infections in individuals
infected with human immunodeficiency virus (HIV), but
certain pneumonias and chronic lung diseases remain
important clinical problems. Subtle immune deficits may
alter the microbial composition in the lung, and these
microbes or their products may impact the host.
Culture-independent techniques, such as 16S ribosomal
RNA (rRNA) gene sequencing, have been instrumental in
identifying bacterial species present in the lung micro-
biome [1]. Alterations in complex microbial communities
have been identified in many diseases compared to healthy
individuals [2]; however, most studies of the lung micro-
biome have primarily described bacterial communities.
These taxonomic analyses of microbial communities
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provide useful information, but have limited insights
into the functional impact of the bacterial micro-
biome. Metabolomics is the scientific study of small-
molecule by-products of host or microbial processes
that are part of an integrated biosystems approach;
they provide a unique molecular fingerprint for an in-
dividual or tissue. The metabolome, which represents
a collection of small molecule features found within
an organism, is dynamic and can reflect various
physiological pathways including bacterial metabolism
and the host inflammatory response. New high-
throughput technologies enable metabolome-wide as-
sociation studies (MWAS) that can support integrated
models for personalized medicine by correlating spe-
cific metabolites with a specific disease.
There are limited data available on the metabolome of
HIV-infected individuals, but metabolomic analyses can
help elucidate interactions between inflammation and
cellular metabolism [3]. A few studies have characterized
the profile of metabolites present in oral wash samples
[4] and cerebrospinal fluid [5]. Most recently, we used li-
quid chromatography-high-resolution mass spectrom-
etry (LC-FTMS) to perform metabolomic analyses of
bronchoalveolar lavage (BAL) fluid of otherwise healthy
HIV-infected and HIV-uninfected individuals [6]. We
demonstrated that overall metabolic profiles in BAL
fluid were different between these two groups and
showed that pyochelin, a siderophore produced by
Pseudomonas aeruginosa, was elevated in the lungs of
HIV-infected individuals compared to HIV-uninfected
individuals [6]. While this study did not investigate mi-
crobial communities in the lung, many of the significant
metabolites identified were not associated with any
known human metabolites and therefore likely produced
by microbial species. Given the potential metabolic
products from bacteria to stimulate host metabolism, in-
vestigation of the relationship of metabolomics and the
microbiota has the potential to provide novel insights
into pathogenic processes.
Thus, we investigated the respiratory microbiota and
global metabolic profiles in the BAL of HIV-infected
and HIV-uninfected individuals to determine if specific
metabolites and bacteria genera were associated with
HIV infection. This study is the first to evaluate the
global functional metabolic interactions between the
microbial species in the lung and the metabolome in
HIV-infected individuals.
Results
Demographics of HIV-infected and HIV-uninfected
participants
Fifty-nine participants were enrolled (39 HIV-infected par-
ticipants and 20 HIV-uninfected); 47 were used for the
training set (32 HIV-infected and15 HIV-uninfected
subjects) while 12 were used for the validation (test) set
(7 HIV-infected and 5 HIV-uninfected). There were no dif-
ferences in race, sex, or smoking status between the groups
(Table 1). The majority of HIV-infected subjects (87.2 %)
reported receiving ART at the time of study, and their me-
dian CD4 count was 600 cells/μl (interquartile range (IQR)
404–853). There was only one HIV-infected individual with
a CD4 count below 200 cells/μl Additional file 1.
Lung microbiota did not distinguish HIV-infected from
HIV-uninfected individuals
Taxonomic assignment of the operational taxonomic
units (OTUs) revealed a total of 153 bacterial taxa across
all samples. The microbial lung communities in these
participants fell into one of two “pulmotypes,” domi-
nated by either the order Actinomycetales or the order
Bacteroidales; in the latter, we see a combination of the
family Prevotellaceae and the family Streptococcaceae.
These types did not sort by HIV status. When using
principal coordinate analysis (PCoA) of the weighted
Table 1 Demographics of HIV-infected and HIV-uninfected participants
Variables HIV (+), n = 39 HIV (−), n = 20 p value
Gender, n (% male) 31 (79.5) 15 (75.0) 0.69
Race, n (%) 0.51
White 20 (51.3) 13 (65)
Black 18 (46.1) 7 (35)
Other 1 (2.6)
Ever smokers, n (%) 24 (61.5) 10 (50.0) 0.40
Current smokers, n (%) 10 (25.6) 5 (25.0) 0.82
CD4 cell count, amedian cells/μl (IQR) 600 (404–853) 1137 (767–1272) 0.008
CD4 count ≤200, n (%)a 1 (2.6)
Currently taking antiretroviral therapy, n (%) 34 (87.2)
Simpson’s Diversity Index, mean (SD) 0.71 (0.26) 0.81 (0.12) 0.96
aSample size is different than above: HIV (+), n = 38 and HIV (−), n = 6
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UniFrac distance between all OTUs identified, the samples
also did not cluster or separate by HIV status (Fig. 1).
Unlike principal component analysis (PCA), PCoA can
use the weighted UniFrac distance between samples, which
incorporates both phylogenetic and compositional differ-
ences in communities. Comparison of intra-group beta di-
versity showed a significant difference in UniFrac distances
between the HIV-infected and HIV-uninfected subjects,
suggesting a higher degree of heterogeneity among the mi-
crobial composition of the lower airways in HIV-infected
subjects. Furthermore, there was no difference in biodiver-
sity, as measured by Simpson’s Diversity Index (Table 1).
There was also no difference in community composition
based on institution where the samples were collected.
These findings indicate that there were no significant differ-
ences between the lung microbiota of our HIV-infected and
HIV-uninfected groups.
Metabolomics of bronchoalveolar lavage fluid distinguish
HIV-infected from HIV-uninfected individuals
We compared the metabolomics features found in the
BALs of the HIV-infected and HIV-uninfected groups.
Of the 5930 mass-to-charge ratio (m/z) features identified
by C18 chromatography, 12 were significantly different be-
tween the HIV-infected and uninfected individuals at a
false discovery rate (FDR) = 0.2 (Appendix 1). Unadjusted
raw data for these 12 features were also evaluated to deter-
mine statistical significance. A logistic regression model
using the top three features (p < 0.0002; FDR 0.05) as
predictors gave an area under the curve (AUC) of 0.89
and 0.80, respectively, for the 47 training samples and
12 independent test samples (7 HIV-infected vs. 5 HIV-
uninfected) used only for validation (see Additional file 2).
The 10-fold cross-validation classification accuracy for the
47 training samples was 90.8 %, and the overall classifica-
tion accuracy for the 12 test samples was 83.3 % using the
logistic regression model. Further, PCoA of 12m/z fea-
tures from C18 chromatography shows not only that the
lung metabolome distinguishes HIV status but also that
there is decreased variability in the metabolome among
HIV-infected subjects compared to HIV-uninfected
subjects (Fig. 2). Using the PCoA analysis allowed for a dir-
ect comparison to the microbiota data. Network analysis of
the 12 differentiating m/z features based on Pearson correl-
ation showed an additional 79m/z features that correlated
with these features with a |r| > 0.40 at FDR = 0.2.
Further metabolite analysis demonstrated that four
features were significantly overrepresented in the BAL fluid
of HIV-infected individuals compared to HIV-uninfected,
including cystine, two complex carbohydrates and 3,5-
dibromo-L-tyrosine (see Additional file 2). Cystine was
measured in the BAL fluid using LC-FTMS, as done previ-
ously [3] and showed increased concentrations among
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Fig. 1 Principal coordinate analysis (PCoA) plot showing the clustering trend of bronchoalveolar (BAL) samples based on the weighted UniFrac
distance. PCoA plot showing the clustering trend of bronchoalveolar (BAL) samples based on the weighted UniFrac distance between all OTUs
identified in HIV-infected (n = 39) and HIV-uninfected (n = 20) individuals. In this cohort, the lung microbiota does not distinguish HIV status, but
comparison of intra-group beta diversity showed a significant difference in UniFrac distances between the HIV-infected and HIV-uninfected
subjects, suggesting a higher degree of heterogeneity among the microbial composition of the lower airways in HIV-infected subjects
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HIV-infected subjects compared to HIV-uninfected sub-
jects; this increase was however not statistically significant
(7.3 (IQR 3.2–16.9) μM vs. 4.3 (IQR 3.6–9.7) μM, p = 0.53).
There were 231m/z features significantly associated
with peripheral blood CD4 cell counts using sparse
partial least squares regression (sPLS) at a variable im-
portance on projection (VIP) threshold of 2 (Fig. 3).
One-way hierarchical cluster analysis (HCA) showed that
these features were grouped into 58 clusters based on the
CD4 cell count. Metabolite annotation and pathway
enrichment analysis using Mummichog mapped these
231m/z features to a number of inflammatory path-
ways, including fatty acid activation (Table 2).
Integration of microbiome and metabolome
Global integration using sPLS regression of all 5930m/z
features with the 153 microbial taxa identified showed
that 109 microbial genera were associated with all features.
Of the 91m/z features associated with HIV, 23 were also
found to be associated with 29 microbial genera at a correl-
ation of 0.30 (Fig. 4a). The bacteria associated at the highest
correlation with the greatest number of these 23 features
included the families Caulobacteraceae (11 features),
Staphylococcaceae (12 features), Nocardioidaceae (12
features), and the genus Streptococcus (7 features).
Streptococcus and its associated m/z features were in a
separate network compared to the other three bacterial
families, as illustrated in the network analysis (Fig. 4b).
Using Mummichog, metabolite annotation and pathway
enrichment analysis was done using the m/z features
that were associated with these three bacteria families—
Staphylococcaceae, Caulobacteraceae, and Nocardioida-
ceae. Staphylococcaceae is shown in Fig. 4b as the represen-
tative family since pathways were similar for all three. This
analysis shows that the metabolic pathways affected most
significantly included lineolate, glycerophospholipid, and
fatty acid metabolism. Pathway analysis could not be done
for Streptococcus given the limited number of features.
Discussion
We investigated the correlation between the lung micro-
biota and global metabolic pathways in the BAL of HIV-
infected individuals to determine if specific features were
altered in relation to HIV infection and to the microbial
composition in the lung. The interactions of microor-
ganisms with the host and the environment could lead
to the development of a variety of diseases and contribute
to their severity. Metabolomic analyses allow us to meas-
ure both metabolic changes in the host and in bacteria. A
recent study in cystic fibrosis patients identified significant
relationships among P. aeruginosa-isolate growth behavior,
forced expiratory volume in one second, and differing
metabolomics clusters [7], suggesting that bacterial species
in the lungs are affecting metabolic composition and po-
tentially resulting in adverse clinical outcomes. We previ-
ously found that metabolomic profiles in BAL fluid
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Fig. 2 Principal coordinate analysis (PCoA) analysis of 12m/z features from C18 chromatography. PCoA analysis of 12m/z features from C18
chromatography shows that the lung metabolome does distinguish HIV-status and there is decreased variability in the metabolome in HIV-infected
subjects compared to HIV-uninfected subjects
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differentiated HIV-infected from HIV-uninfected individ-
uals [6], but it was unclear if those patterns related to bac-
terial communities. The current study has combined these
two modalities and identified a number of clinically rele-
vant features that are altered with respect to specific lung
microbial communities in HIV-infected individuals.
We found that specific metabolic pathways were not
only associated with HIV status but specific metabolites
were also increased in the BAL fluid of HIV-infected in-
dividuals compared to HIV-uninfected individuals, one
of the most intriguing being cystine. Cysteine, an essen-
tial amino acid, is a rate-limiting component of glutathione
synthesis and plays an important role in maintaining the
detoxification of free radicals and reactive oxygen species
[8, 9]. It is also an integral part of fatty acid synthesis [10].
Oxidative stress can be generated through several mecha-
nisms including the oxidation of extracellular thiols, in par-
ticular cysteine to cystine [9], and HIV infection is known
to cause oxidative stress [11–13]. Cysteine supply is limit-
ing for important lymphocyte functions and impaired in
HIV [14, 15]. In fact, treatment with N-acetylcysteine has
been studied in ART-naïve HIV-infected patients [16, 17]
and shown relative increases in CD4+ T cell numbers.
In our study, we observed that oxidized cysteine, or cyst-
ine, concentrations were increased in HIV-infected individ-
uals and that CD4 counts were also associated with fatty
acid metabolism. Further, fatty acid metabolism in addition
to glycerophospholipid and linoleate metabolic pathways
also correlated with the lung microbial species in these
HIV-infected individuals; these have previously been shown
to be altered systemically in HIV-infected individuals [18].
High dietary linoleic acid can lead to excessive
prostaglandin-E2 production, which can depress cellular
immunity specifically associated with the Th1 subset of T
cells, which is also reduced in HIV infection [19, 20]. Alter-
ations in surfactant glycerophospholipid have been seen in
AIDS patients with acute Pneumocystis pneumonia [21].
Most recently, using combined metabolomic and qRT-PCR
analyses, HIV-1 Tat protein was noted to cause significant
alterations in glycerophospholipid metabolism [22]. These
data suggest that HIV infection alters these metabolic path-
ways systemically. We now show that these perturbations,
which are associated with pathogenic bacteria, are also
present in the lung.
The bacterial organisms associated with the highest
number of metabolic features—Caulobacteraceae, Sta-
phylococcaceae, and Nocardioidaceae—are known
causative organisms in the pathogenesis of pneumonia
in HIV-infected patients. Staphylococcaceae are gram-
positive organisms that include the genus Staphylococ-
cus. Together with Streptococcus, these are two of the
most frequent organisms seen in the era of ART and
are often responsible for the greatest incidence of
community-acquired pneumonia in HIV-infected
adults and children [23]. Similarly, Nocardioidaceae is
a family of bacteria with several genera including
Norcardia and Rhodococcus. Norcardia are gram-
positive organisms with partial acid-fast branching
filaments that can be isolated in the soil worldwide,
while Rhodococcus equi is a gram-positive coccobacillus
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Fig. 3 Association of peripheral CD4 cell counts with metabolomic
features using sPLS at a variable importance on projection (VIP)
threshold of 2. Association of peripheral CD4 cell counts with
metabolomic features shows that 231m/z features were found to be
significantly associated with CD4 count using partial least squares
(PLS) regression at variable importance on projection threshold of 2.
Metabolite annotation and pathway enrichment analysis using
Mummichog mapped these 231m/z features to inflammatory pathways,
including fatty acid activation and arginine metabolic pathways
Table 2 Metabolite annotation and pathway enrichment
analysis using Mummichog for 231 m/z features associated with
CD4 cell count
Pathways Pathway size p value
Vitamin E metabolism 30 0.002
Urea cycle/amino group metabolism 37 0.004
Fatty acid activation 23 0.005
Arginine and proline metabolism 30 0.01
Aspartate and asparagine metabolism 55 0.02
Starch and sucrose metabolism 16 0.02
Linoleate metabolism 18 0.03
Fatty acid metabolism 22 0.04
Butanoate metabolism 23 0.04
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that can also cause pneumonia in HIV-infected individuals
[24]. Caulobacteraceae, an alpha-Proteobacteria, is com-
mon in aquatic and soil environments. It was re-
cently shown that HIV-infected individuals who use
cocaine display intestinal dysbiosis resulting in an
abundance of Proteobacteria in their feces com-
pared to HIV-uninfected controls [25]. It is possible
that this organism, although mainly found in the
gut, may be important for HIV pathogenesis in the
lung as well. The Caulobacteraceae were not found
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Fig. 4 a Three-way relationship between metabolome, HIV, and microbiota integration of HIV-specific m/z features with microbiota data at correlation
of 0.3. This figure shows that of the 91m/z features associated with HIV, 23 were also found to be associated with 29 microbial genera at a correlation
of 0.30; red circles microbial families and genus, blue rectangles metabolome features. b Pathway analysis using m/z features that were associated with
Staphylococcaceae in the global network. Using Mummichog, metabolite annotation and pathway enrichment analysis was done using the m/z features
that were associated with Staphylococcaceae (as the representative bacteria since pathways for Caulobacteraceae and Nocardioidaceae were
very similar). The y-axis represents the enrichment significance of the metabolic pathways. This analysis shows that the pathways most affected included
lineolate, glycerophospholipid, and fatty acid metabolism
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in the reagent controls or in the relevant BAL
controls.
Based on our results, we postulate that HIV infec-
tion alters inflammatory and oxidant metabolic path-
ways within the lung, which then shift the functional
properties of the lung microbiome and/or the host re-
sponse to the lung microbiome (Fig. 5). The resulting
increase in inflammation and oxidative stress may fur-
ther impair lung host immunity leading to an in-
creased risk of pneumonia or to chronic lung disease
associated with HIV. In addition, alterations in redox
balance may further influence the function of the
microbiome and metabolome leading to a dynamic
imbalance within the lung.
This study has several limitations. With respect to
the microbiota data, we did not explicitly account for
contamination (from the environment or upper air-
ways). Although some investigators have noted that
BAL fluid samples are not affected by upper airway
contamination [26], others have not corroborated this
finding [2]. However, by limiting our analyses to the
153 genera with >5 % relative abundance in all BAL
samples, we were able to separate the BAL samples
from the reagent controls. Another limitation is that
this study only focuses on bacterial communities
while other organisms, such as fungi, may also be im-
portant [27]. With respect to metabolomics, this
study does not distinguish microbial from host meta-
bolic products; however, given the prominent associa-
tions between the lung microbiota and metabolic
profiles, it demonstrates potentially important rela-
tionships for future study. In addition, authenticated
standards are not available for many of the features
we identified, and so the 91m/z features of interest
have not all been validated. Metabolome data was
also not adjusted for BAL or serum urea, which could
have introduced error. Further, although 12m/z fea-
tures were significantly different between HIV-
infected individuals and controls, these results were
marginally significant at a FDR of 20 % and should
be interpreted with some caution.
Conclusions
In summary, we have performed the first study to investi-
gate the respiratory microbiome-metabolome interaction
in HIV-infected individuals. We found 12 metabolic fea-
tures in BAL that differentiated between HIV-infected and
HIV-uninfected participants, and another 79 features were
identified in network analysis. Further metabolite analysis
demonstrated that cystine was one of four features that
were significantly overrepresented in the BAL fluid of
HIV-infected individuals compared to HIV-uninfected
and cystine concentrations were increased among HIV-
infected subjects compared to HIV-uninfected subjects,
albeit not statistically significant. Metabolome associations
with CD4 counts also showed alterations in inflammatory
pathways. Several HIV-differentiating metabolites, including
those involved in inflammatory pathways, correlated with
lung microbes known to cause lung infections. Further in-
vestigation into other aspects of innate lung immunity and
the interaction between these organisms and the host im-
mune response will be critical as this field moves forward.
These findings may lead directly to a better understanding
of the interactions of microbial communities, host physi-
ology, and lung disease in HIV.
Methods
Study population
Fifty-nine participants from the Pittsburgh Lung HIV
cohort were recruited to undergo bronchoscopy at the
shifts in microbiota
(bacteria & fungi)
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impaired lung 
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risk for
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Fig. 5 Overall schema. Overall schematic that postulates that HIV
infection alters metabolomic profiles in lung (inflammatory and
oxidant pathways) which causes a shift in the functional properties
of the lung microbiome and/or in the host response to the lung
microbiome which may lead to an increased risk of lung infection or
to chronic lung disease associated with HIV
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University of Pittsburgh, the University of California San
Francisco, and the University of California Los
Angeles [28, 29]. The lung HIV cohort enrolled a
total of 396 HIV-infected and HIV-uninfected individ-
uals from 2008 through 2011 from the Multicenter
AIDS Cohort Study (MACS) and the Women’s Inter-
agency HIV Study (WIHS) cohorts. Inclusion criteria
for the bronchoscopy study included the absence of
acute respiratory symptoms or fever in the previous
four weeks and use of systemic antimicrobials (ex-
cluding antiretroviral treatments) or immunosuppres-
sive medications within 6 months. We obtained
clinical and demographic data by standardized subject
interview and medical record review. Written in-
formed consent was obtained from all participants
after approval of human subjects’ protection protocols
from review boards of the University of Pittsburgh,
the University of California San Francisco, the Uni-
versity of California Los Angeles, and Emory Univer-
sity. The study was registered at clinicaltrials.gov
(NCT00870857). Microbiota data from a subset of
these individuals has been previously reported as part
of the NHLBI’s Lung HIV Microbiome Project collab-
oration [30].
Sample collection
Subjects were asked to fast and to refrain from smoking
for at least 12 h before sample collection. Bronchoscopy
with BAL was performed according to standardized pro-
cedures designed to minimize oral contamination [31].
BAL was performed by sequentially instilling and then
withdrawing 50 ml aliquots of sterile normal saline up to
a total of 200 ml into the right middle lobe or lingula.
Sample processing and sequencing
DNA was extracted from samples using the Power Soil
Extraction kit (Mo Bio, USA). Sequencing was performed
using the Roche 454 FLX Titanium platform with primers
for the amplification of hypervariable regions 1 through 3
(V1–3) of the 16S rRNA gene, as previously described [2].
Sequence reads were trimmed and analyzed using the
QIIME software package [32]. These were then clustered
into OTUs and used to characterize the diversity of the
lung microbiota in the BAL. Specifically, to estimate the
richness and evenness of the microbial community for
each BAL sample, we calculated Simpson’s Diversity
Index. To determine the phylogenetic and compositional
differences between the microbial communities across the
samples, we calculated weighted UNIFRAC distances [33]
between pairs of samples. Intra-group beta diversities were
also compared. Taxonomic assignment of the OTUs was
performed down to the genus level, and genera with less
than 5 % relative abundance in all samples were removed,
leaving a total of 153 microbial genera across samples.
Metabolomics
Samples were analyzed by LC-FTMS, as previously
described [3]. m/z features were collected by a
Thermo Q Exactive Hybrid Quadrupole-Orbitrap
Mass Spectrometer (Thermo Fisher, San Diego, CA)
from m/z 85 to 1275 over 10 min. Peak extraction,
noise removal, and quantification of ion intensities
were performed by an adaptive processing software
package (apLCMS) with xMSanalyzer designed for use
with LC-FTMS data [34]. For clarification, data ex-
tracted on m/z features, which are not definitively identi-
fied metabolites, will be referred to as “features” and not
metabolites. See Additional file 2.
Biostatistics and bioinformatics
The major predictor variable was HIV infection
status. Two-sample Wilcoxon rank-sum tests were
performed to compare continuous demographic char-
acteristics between HIV-infected and HIV-uninfected
individuals. Pearson chi-square tests were used to
compare categorical characteristics. Statistical analyses
were conducted in NCSS statistical software, except
as indicated below. All reported p values were two-
sided; and p-values of less than 0.05, corrected for
multiple hypotheses testing as necessary, were consid-
ered statistically significant.
High-resolution mass spectral data were filtered to
include only m/z features where at least one group
(HIV-infected or HIV-uninfected) had values for 50 %
of the samples. A total of 5930m/z features were se-
lected and used for all statistical analyses. LIMMA
package [35] in R (linear models for microarray data)
in Bioconductor was used to identify differentially
expressed features at a significance threshold of 0.2
after Benjamini-Hochberg FDR adjustment. Two-way
HCA was performed to identify clusters of individuals
associated with discriminating clusters of features.
Principal component analysis using Pirouette version
4.0 (InfoMetrix) was performed, as previously described
[36]. Metabolite annotation and pathway enrichment ana-
lysis was done using Mummichog software implementa-
tion of an approach that uses the collective power of
combining metabolite identification and metabolic
pathway/network analysis into one site. The sPLS re-
gression method [37] implemented in the R package
mixOmics was used to perform integration and
visualization of microbiome × metabolome associa-
tions. See Additional file 2.
Availability of data
The sequence data supporting the results of this study is
available in NCBI sequence read archive (SRA) under
accession SRP065274.
Cribbs et al. Microbiome  (2016) 4:3 Page 8 of 11
Appendix 1
Additional files
Additional file 1: Bal public dataset. (XLSX 12 kb)
Additional file 2: Figures S1 and S2. Figure S1. Receiver operating
characteristic (ROC) curve using the top discriminatory features between
HIV-infected (n = 32) and HIV-uninfected (n = 15) individuals. The top
three features (p < 0.0002; FDR 0.05) were used as predictors in a logistic
regression model that gave an area under the curve (AUC) = 0.89 and a
10-fold cross-validation classification accuracy of 90.8 % for the 47 training
samples and AUC of 0.8 and classification accuracy of 83.3 % for the 12 test
set samples. Dotted line training set (n = 47). Solid line validation (test)
set (n = 12). Figure S2. Metabolomics of bronchoalveolar (BAL) fluid of
HIV-infected individuals compared to HIV-uninfected. Further metabolite
analysis demonstrates that four features were significantly over-represented
in the bronchoalveolar lavage (BAL) fluid of HIV-infected individuals
compared to HIV-uninfected, including cystine, two complex carbohydrates
and 3,5-dibromo-L-tyrosine. (PDF 106 kb)
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Input mass Adduct Mass Database matcha Formula p (Limma)
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570.3873606 [M + Na]+ 547.4002 PC(O-3:1(1E)/O-18:1(9Z))[S] C29H58NO6P 0.0007
1189.600044 [M + H]+ 1188.5928 Camelliasaponin A1 C58H92O25 0.0009
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529.8652782 No match 9.96*10−7
272.1645049 [M + H]+ 271.1572 Apoatropine C17H21NO2 0.0023
aMatched in Metin at 10 ppm
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